On this page
VPS16
VPS16 core subunit of CORVET and HOPS complexes
VPS16 encodes a protein essential for cellular membrane trafficking and lysosomal function, with variants linked to neurological and metabolic conditions. The VPS16 gene provides instructions for making a core component of two protein complexes, CORVET and HOPS, which coordinate the movement of materials within cells.
VPS16 is located on the short (p) arm of chromosome 20, at band 20p13. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 20 in the library →Overview
VPS16 encodes VPS16 core subunit of CORVET and HOPS complexes, a protein that plays a central role in organising membrane trafficking within cells. The protein is a structural component of two multi-subunit complexes: CORVET, which operates in early endosomal pathways, and HOPS, which functions in late endosomal and lysosomal fusion events. Both complexes are essential for maintaining the compartmentalisation and function of the endolysosomal system, the network of membrane-bound structures responsible for processing, degrading, and recycling cellular materials.
Disruption of VPS16 function can impair lysosomal activity and cellular waste management, leading to the accumulation of unprocessed molecules. Pathogenic variants in this gene have been associated with neurological phenotypes and are recognised on UK clinical genomic panels for movement disorders and metabolic conditions, reflecting the gene's importance in neurogenetics and lysosomal biology.
What the gene does
The VPS16 protein functions as a core subunit within two tethering complexes that coordinate membrane fusion events in the endolysosomal pathway. In the CORVET complex, VPS16 facilitates the tethering and fusion of early endosomes, ensuring that newly internalised cargo is sorted correctly. In the HOPS complex, the protein participates in late endosomal maturation and fusion with lysosomes, enabling the delivery of hydrolytic enzymes and substrates for degradation.
These tethering complexes work by bringing membrane compartments into close proximity before SNARE proteins complete the fusion process. VPS16 provides a structural scaffold that stabilises the complexes and coordinates interactions with other trafficking machinery. The protein's activity is particularly critical in neurons and other metabolically active cells, where efficient lysosomal function is necessary to clear damaged proteins and organelles. Disruption of VPS16-mediated trafficking can lead to the accumulation of undegraded materials, contributing to cellular dysfunction and the development of neurological and metabolic phenotypes.
Video: Genetics 101
Chromosome location
VPS16 is located on the short arm of chromosome 20 at position 20p13. The gene spans approximately 15 kilobases of genomic DNA and contains 21 exons, with the principal transcript encoding the 839-amino-acid VPS16 protein. Several alternative transcripts have been described in public reference databases (RefSeq and Ensembl), though the canonical isoform is the one most relevant to known disease associations.
Protein structure
The VPS16 protein is 839 amino acids in length and contains conserved structural elements that enable its participation in both CORVET and HOPS complexes. A functionally important region, mapped to approximately amino acids 642 to 736, mediates interaction with VPS33A, a key component shared by both complexes. This interaction domain is essential for stabilising the multi-subunit architecture and coordinating the recruitment of SNARE proteins during membrane fusion. The overall domain organisation allows VPS16 to serve as a structural hub within the tethering machinery.
Key variants
Pathogenic variants in VPS16 can disrupt the protein's ability to stabilise tethering complexes or interact with partner subunits, leading to impaired endolysosomal trafficking. VPS16-related disorders most commonly follow an autosomal recessive inheritance pattern, meaning two pathogenic variants (one inherited from each parent) are typically required for disease to develop. Rare reports have suggested heterozygous variants in association with early-onset dystonia, though the evidence base is limited and recessive inheritance remains the established primary pattern. Loss-of-function changes are generally associated with more severe phenotypes, whilst some missense variants may partially preserve protein function.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1335T>G | p.Tyr445Ter | Pathogenic | ★★☆☆ | Dystonia 30 |
c.1389C>G | p.Tyr463Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Dystonia 30 |
c.1903C>T | p.Arg635Ter | Pathogenic | ★★☆☆ | not provided |
c.1326T>A | p.Tyr442Ter | Pathogenic | ★☆☆☆ | not provided |
c.1955dup | p.Thr653fs | Pathogenic | ★☆☆☆ | Dystonia 30 |
c.436del | p.Ile146fs | Pathogenic | ★☆☆☆ | not provided |
c.539G>A | p.Trp180Ter | Pathogenic | ★☆☆☆ | Dystonia 30 |
c.694C>T | p.Arg232Ter | Pathogenic | ★☆☆☆ | not provided |
c.721_727del | p.Gly241fs | Pathogenic | ★☆☆☆ | not provided |
c.1094_1095dup | p.Tyr366fs | Pathogenic | - | Dystonia 30 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
VPS16 variants are best recognised as a cause of VPS16-related dystonia (sometimes referred to as DYT-VPS16), a movement disorder that typically begins in childhood or adolescence, although later-onset presentations into early adulthood have also been described. The dystonia is often generalised, frequently involving the limbs, neck, and craniofacial muscles, and may progress over time. Some individuals additionally show features such as chorea, parkinsonian signs, or cognitive involvement. Biallelic variants have also been linked to phenotypes consistent with inborn errors of metabolism and features overlapping the lysosomal storage disorder spectrum, reflecting the gene's role in endolysosomal trafficking. Severity is highly variable between individuals, even within the same family, and prognosis depends on the specific variants and clinical features involved. A clinical genetics or neurogenetics specialist can provide individualised interpretation.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic VPS16 variants typically follow ad/ar inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
VPS16 is included on several UK NHS Genomic Medicine Service panels, reflecting its clinical relevance in diagnosing inherited neurological and metabolic conditions. The gene has been classified with green (high evidence) status on the Adult onset dystonia, chorea or related movement disorder panel (R56), the Childhood onset dystonia, chorea or related movement disorder panel (R57), the Likely inborn error of metabolism panel (R98), and the Lysosomal storage disorder panel (R276). This broad panel representation indicates that VPS16 variants are recognised as clinically actionable in multiple diagnostic pathways within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What do the CORVET and HOPS complexes do?
CORVET and HOPS are multi-protein complexes that tether cellular membrane compartments together before they fuse. CORVET operates in early endosomal pathways, whilst HOPS functions in late endosomal and lysosomal fusion, both ensuring proper trafficking of cellular materials.
How are VPS16 variants inherited?
VPS16-related disorders most commonly follow an autosomal recessive pattern, meaning two pathogenic variants (one from each parent) are typically needed for disease to develop. Carriers with a single variant are usually unaffected. Rare reports have suggested dominant-acting heterozygous variants in early-onset dystonia, but recessive inheritance remains the established primary pattern.
Why is VPS16 on multiple NHS genomic panels?
VPS16 is included on panels for movement disorders, metabolic conditions, and lysosomal storage disorders because its protein product is essential for lysosomal function, and disruption can lead to diverse neurological and metabolic phenotypes.
What condition is VPS16 most associated with?
VPS16 is best known for causing VPS16-related dystonia (DYT-VPS16), a movement disorder that typically begins in childhood or adolescence and often becomes generalised over time. Additional features such as chorea, parkinsonism, or metabolic involvement can occur, and severity varies considerably between individuals.